Traders should monitor the upcoming topline data from the NATiV3 trial in Q4 2026, as positive results could offset current negative fundamentals. However, the widening net losses and declining revenue present significant near-term headwinds for the stock price.
Price Chart
Executive Summary
Inventiva S.A. reported a significant decline in revenue to $4.5 million in 2025 from $9.2 million in 2024, driven by lower licensing income. Despite raising $172.5 million in a U.S. public offering and extending its cash runway to Q1 2027, the company incurred a wider net loss of $354.1 million. The company's stock price may face pressure due to declining revenue and increased losses, even as it advances its pivotal NATiV3 trial for lanifibranor.
Key Facts
- Revenues declined to $4.5 million in 2025 from $9.2 million in 2024
- Net loss widened to $354.1 million in 2025 from $184.2 million in 2024
- Cash and short-term deposits totaled $230.9 million as of December 31, 2025
- Company raised $172.5 million in a U.S. public offering in November 2025
- Cash runway extended to middle of Q1 2027
- Completed enrollment in NATiV3 Phase 3 trial with topline results expected in Q4 2026
Financial Impact
Revenue declined by $4.7 million (51%) year-over-year, while net losses increased by $169.9 million (92%)
Risk Factors
- Failure of NATiV3 trial could severely impact stock price
- Continued revenue decline if licensing deals don't materialize
- Potential need for additional capital beyond 2027 runway
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001104659-26-040704 |
| Document: iva-20251231xex2d4.htm | 0001104659-26-040704 |
| Document: iva-20251231xex1d1.htm | 0001104659-26-040704 |
| Document: iva-20251231xex11d1.htm | 0001104659-26-040704 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 19w ago | 6-K | $5.33 $3.59 | ▼ −32.65% | ▼ −39.50% | $3.18 (−40.34%) |
Jun 3, 2026 20w ago | 6-K | $5.33 $3.59 | ▼ −32.65% | ▼ −35.14% | $3.18 (−40.34%) |
Jun 2, 2026 20w ago | 6-K | $5.33 $3.59 | ▼ −32.65% | ▼ −35.14% | $3.18 (−40.34%) |
May 26, 2026 21w ago | 6-K | $5.33 $3.59 | ▼ −32.65% | ▼ −34.52% | $3.18 (−40.34%) |
May 22, 2026 22w ago | 6-K | $5.33 $3.59 | ▲ +32.65% | ▲ +35.37% | $3.18 (+40.34%) |
Apr 8, 2026 28w ago | 20-F | $5.50 $3.59 | ▲ +34.73% | ▲ +45.18% | $3.18 (+42.18%) |
Mar 30, 2026 30w ago | 6-K | $5.50 $3.59 | ▼ −34.73% | ▼ −47.11% | $3.18 (−42.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers